title: Heterogeneity of biological bone markers in idiopathic male osteoporosis.
abstract: In men with idiopathic osteoporosis, histomorphometric studies reported both increased resorption and decreased remodeling. We aimed at examine bone remodeling in these patients by biological marker measurement. We compared pre-treatment carboxy-terminal cross-linking telopeptide of type I collagen (CTX) and bone alkaline phosphatase (bALP) levels in 49 men, mean age 59 ± 14 year, with idiopathic osteoporosis with fractures (40 patients) or osteoporosis diagnosed by densitometry (9 patients) with 50 age-matched controls. The influence of baseline remodeling level on alendronate efficacy was studied. Bone remodeling markers (CTX and bALP) did not significantly differ between patients and controls and were correlated in both groups. There was no correlation between these markers, vitamin D and PTH levels. Twenty-one patients underwent repeat densitometry after 1 year of alendronate (70 mg/week). Mean annual BMD increase, spine +4.1 ± 3.9%, and hip +1.5 ± 1.2% showed no correlation with baseline CTX. Bone remodeling is very heterogeneous and formation and resorption remain biologically coupled in both idiopathic male osteoporosis and controls. Baseline remodeling level does not affect the action of alendronate on BMD.
authors.affiliation: Centre de Rhumatologie, CHU Purpan, 1 Place du Dr Baylac, 31059, Toulouse Cedex, France. laroche.m@chu-toulouse.fr
authors.forename: Michel
authors.initials: M
authors.lastname: Laroche
mesh_terms: D000328:Adult; D000368:Aged; D019386:Alendronate / Q000627:therapeutic use; D000469:Alkaline Phosphatase / Q000097:blood; D015415:Biomarkers / Q000097:blood; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D016723:Bone Remodeling; D001842:Bone and Bones / Q000737:chemistry / Q000378:metabolism*; D024042:Collagen Type I / Q000097:blood; D003720:Densitometry; D006801:Humans; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000473:pathology*; D058866:Osteoporotic Fractures / Q000000981:diagnostic imaging / Q000209:etiology / Q000517:prevention & control; D010281:Parathyroid Hormone / Q000097:blood; D010455:Peptides / Q000097:blood; D011859:Radiography; D014807:Vitamin D / Q000097:blood
chemical_list: D015415:Biomarkers; D050071:Bone Density Conservation Agents; D024042:Collagen Type I; C470125:PTH protein, human; D010281:Parathyroid Hormone; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide; D014807:Vitamin D; D000469:Alkaline Phosphatase; D019386:Alendronate